NanoViricides closes $3.8 million offering, cuts ATM capacity to zero

NanoViricides, Inc. closed its previously priced registered direct offering on July 27, 2026, according to an 8-K filing. The offering closed on that date, with aggregate gross proceeds to the company of approximately $3.8 million, before deducting the placement agent's fee and offering expenses.¹

The final structure included 2,416,339 shares of common stock at $1.53 per share, pre-funded warrants for up to 100,000 shares at $1.52999 per warrant, and accompanying common warrants for up to 2,516,339 shares.¹ Each common warrant is exercisable for one share at $1.75, becomes exercisable six months from issuance, and expires five and one-half years from issuance.¹

The company agreed for 60 days after closing not to issue or announce new common stock or equivalents, or file new registration statements, apart from a resale registration statement or an S-8 plan filing.¹ Separately, it agreed to file within 30 days of closing a resale registration statement covering shares issuable upon exercise of the warrants, and to use commercially reasonable efforts to keep it effective.¹

The CEO and principal stockholder TheraCour Pharma, Inc. entered lock-up agreements barring sales or transfers of their shares for 30 days following the closing date.¹

D. Boral Capital LLC, the placement agent, is entitled to a cash fee of 7.0% of gross proceeds plus reimbursement of up to $50,000 in fees and expenses.¹ The company said it intends to use net proceeds for working capital, capital expenditures, research and development, clinical trial expenditures, and possible acquisitions or other strategic purposes.¹

A separate amendment dated July 27, 2026 updates the company's at-the-market program with D. Boral Capital. The filing cover page now lists "Up to $0 of Common Stock" available under that facility.² As of July 23, 2026, the company's non-affiliate public float was calculated at $41,583,701, based on 22,356,829 shares at $1.86 per share.² The company said it had already sold about $9,843,165 of stock under the relevant Form S-3 instruction during the trailing 12 months.² As a result, the company said it is decreasing the maximum amount eligible for sale and currently cannot offer or sell common stock through the agent under the amended terms.²